Faes Farma, S.A.

MCE FAE.MC

Faes Farma, S.A. Return on Equity (ROE) for the year ending December 31, 2023: 13.88%

Faes Farma, S.A. Return on Equity (ROE) is 13.88% for the year ending December 31, 2023, a -6.81% change year over year. Return on equity measures profit against shareholder equity; higher ROE indicates superior profitability and value creation.

Faes Farma, S.A. Return on Equity (ROE) for the year ending December 31, 2022 was 14.89%, a -3.04% change year over year.
Faes Farma, S.A. Return on Equity (ROE) for the year ending December 31, 2021 was 15.36%, a -0.22% change year over year.
Faes Farma, S.A. Return on Equity (ROE) for the year ending December 31, 2020 was 15.39%, a -0.63% change year over year.
Faes Farma, S.A. Return on Equity (ROE) for the year ending December 31, 2019 was 15.49%, a 8.04% change year over year.

Key data

Date	Return on Equity (ROE)	Return on Capital Employed (ROCE)	Interest Coverage Ratio	Debt to Equity Ratio

MCE: FAE.MC

Faes Farma, S.A.

CEO	Mr. Mariano Ucar Angulo
IPO Date	Jan. 3, 2000
Location	Spain
Headquarters	Avenida Autonomía 10
Employees	1,748
Sector	Healthcare
Industries Pharmaceuticals Cleaning Supplies Cosmetics Drugstores & Retail Pharmacies Eyewear Personal Care Pet Food

Description

Faes Farma, S.A., a pharmaceutical company, researches, develops, produces, and commercializes pharmaceutical products and raw materials in Spain and internationally. The company's product portfolio includes prescription drugs, generic drugs, over-the-counter (OTC) drugs, food supplements, baby foods, and other health products. It offers Actimag, a magnesium pidolate; Bilaxten, an anti-allergic; Bronquidiazina CR, an anti-infective; Claversal for ulcerative colitis and Crohn's disease; Dezacor, a corticoid; Dolotren, an anti-inflammatory; Dolotren Gel; Dynamogen, an anti-anorexic; Ferroprotina, an anti-anaemic; Hidroferol; Lipofen; Positon for dermatitis; strength builder products, such as Potenciator and Surmenalit; Pruina, a laxative; Robaxisal Compuesto, a muscle relaxant and analgesic; Trausan, a citicoline; Venosmil, a venous vasoprotector; Venosmil Gel; and Yendol, an anti-flu. The company also provides Bilastine, an antihistamine molecule for the treatment of allergic rhino conjunctivitis and urticarial; Calcifediol for bone metabolism; Deflazacort to treat osteoarticular disease; Hidrosmin for venous insufficiency; and Mesalazine to treat digestion problems. It also exports its products. Faes Farma, S.A. was founded in 1933 and is headquartered in Leioa, Spain.

Key trends

Past 5 years